Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) granted 45,984 restricted stock units of common stock to 23 newly hired non-executive officers. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and granted on August 16, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to continued employment.

Market Context

RARE's prior inducement grant showed a -0.04% 24-hour reaction. That company-specific precedent prov...

Analysis

RARE's prior inducement grant showed a -0.04% 24-hour reaction. That company-specific precedent provides context for the current employee award; net insider activity was selling, a risk factor to monitor alongside execution.

Key Figures

Restricted stock units: 45,984 RSUs Recipients: 23 officers Grant date: August 16, 2026 +2 more

5 metrics

Restricted stock units 45,984 RSUs Grant to newly hired non-executive officers

Recipients 23 officers Newly hired non-executive officers

Grant date August 16, 2026 Inducement award grant date

Vesting period 4 years Restricted stock units

Annual vesting tranche 25% Underlying shares vest on each anniversary

Historical Context

5 past events · Latest: Aug 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 19	FDA approval	Positive	-3.5%	FDA granted accelerated approval for GENGLYCOS gene therapy in GSDIa
Aug 04	Earnings report	Positive	-3.4%	Second-quarter revenue increased while net loss narrowed and guidance was reaffirmed
Jul 28	Earnings scheduling	Neutral	-3.8%	Company scheduled its second-quarter financial results conference call
Jul 24	Inducement grant	Neutral	-0.0%	Company granted restricted stock units to newly hired non-executive officers
Jul 08	Impact report	Neutral	-3.4%	Company released its annual impact report with operating and patient-support metrics

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five selected recent events had negative 24-hour reactions, including the FDA approval and second-quarter earnings announcements.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"reported the grant of 45,984 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What equity awards did Ultragenyx (RARE) report on August 25, 2026?

Ultragenyx reported granting 45,984 restricted stock units of common stock to 23 newly hired non-executive officers. According to Ultragenyx, these awards were made under its Employment Inducement Plan as a hiring incentive consistent with Nasdaq Listing Rule 5635(c)(4).

Who received the new Ultragenyx (RARE) restricted stock units granted in August 2026?

The new restricted stock units were granted to 23 newly hired non-executive officers at Ultragenyx. According to Ultragenyx, the equity awards were an inducement material to these employees entering into employment with the company under its Employment Inducement Plan.

When was the Ultragenyx (RARE) inducement grant dated and how many RSUs were issued?

The inducement grant was dated August 16, 2026 and covered 45,984 restricted stock units. According to Ultragenyx, the compensation committee of the board approved these RSUs as part of its Employment Inducement Plan for newly hired non-executive officers.

How do the Ultragenyx (RARE) August 2026 restricted stock units vest for employees?

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the August 16, 2026 grant date. According to Ultragenyx, vesting is conditioned on the employee’s continuous employment on each vesting date.

Under what plan and Nasdaq rule were Ultragenyx (RARE) inducement RSUs granted in August 2026?

The RSUs were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). According to Ultragenyx, this rule allows equity awards as a material inducement for new employees joining the company.

Why did Ultragenyx (RARE) classify the August 16, 2026 RSU grant as an inducement award?

Ultragenyx classified the grant as an inducement award because it was material to new employees entering into employment with the company. According to Ultragenyx, this structure aligns with its Employment Inducement Plan and Nasdaq Listing Rule 5635(c)(4) requirements.